First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Relapsed biliary tract cancer, and ASCO, beckon.
The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
Golcadomide and iberdomide are set to feature at EHA.
A Libtayo combo fails to beat Keytruda in first-line melanoma.
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
